Pinealon (Glu-Asp-Arg)

Evidence Anchor

BioHarmony 6.4/10

Pinealon sits in caution because it pairs an interesting laboratory mechanism with an almost empty human evidence file. The cell and animal work is coherent, the safety read is mild, and an outside lab confirmed the peptide can contact DNA. But there is no registered human trial, no published effect size for cognition, and the strongest human data is a single uncontrolled cohort of 32 from the lab that invented it. That is not enough to recommend it over options that actually have human evidence behind them. The honest verdict is interesting biology, unproven in people, so spend your money and effort elsewhere unless you are specifically drawn to the bioregulator world and treating it as an experiment. I want to be fair to the science here, because there is a real temptation to dismiss anything from outside the usual Western trial pipeline. The cell-level neuroprotection is genuine, the DNA-contact result is independently confirmed, and the safety picture, as far as it goes, is reassuring. The problem is not that Pinealon has been tested and failed; it is that it has barely been tested in people at all. Caution, not skip, is the right call: it earns the benefit of the doubt on mechanism while staying honest that the human payoff is unproven. ✅ Best for: Peptide-bioregulator hobbyists already deep in the Khavinson protocol who want to round out a cytomax stack and accept the compound is unproven. People running a careful N-of-1 who will track focus and mood honestly and stop if nothing shows. Older adults with lower baseline who, on the thin cohort data, might be the most likely to notice anything, per Meshchaninov 2015. Anyone who can source verified material with a certificate of analysis and is comfortable with grey-market reality. Curiosity-driven self-experimenters who treat it as a low-stakes trial, not a proven tool. ❌ Avoid if: You want an evidence-backed cognitive intervention, because the human data does not exist and Semax or Cerebrolysin are far better supported. You have any active or suspected cancer, since a compound claimed to alter gene expression has no safety data in that setting. You have any blood-count concern, given the reported drop in CD34 progenitor markers, per Meshchaninov 2015. You cannot verify source quality, because grey-market peptides carry purity and sterility risk that can exceed the intrinsic pharmacology, especially for injectables. You are pregnant or breastfeeding, where there is no human safety data at all.

Read the full BioHarmony report

My score and my verdict: one signal of three, never the whole answer.